Aripiprazole Augmentation of Antidepressants in PTSD

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The proposed investigation will determine the therapeutic potential of aripiprazole augmentation to a stable antidepressant regimen for reducing posttraumatic stress disorder (PTSD) symptoms, cognitive symptoms, psychotic symptoms, and depressive symptoms in veterans with PTSD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Durham VA Medical Center
• Treatments: Antidepressive Agents; Aripiprazole

Criteria

Inclusion Criteria:

• Outpatient veterans with posttraumatic stress disorder (PTSD)

• Receiving treatment with an antidepressant at a stable dose for 4 weeks

• Male or female

• Ages 18-65 years old